Nuclein LLC announces plans to expedite the commercialization of its Nuclein™ Hand-Held PCR Test. The company’s disposable, all-in-one, self-test device for infectious disease diagnosis does not require technical expertise and provides battery-powered, sample-to-answer results in under one hour, without the need to mail in a sample. The company anticipates moving into product manufacturing soon, with the objective of launching its COVID-19 Hand-Held PCR Test by fall 2020.
This announcement represents Nuclein’s first public release of information about its patent-pending technology and serves as a response to the call for a “Manhattan Project” for diagnostic testing. This also serves as a response to White House Coronavirus Response Coordinator Dr. Deborah Birx’s interest in developing a COVID-19 self-test.
Please note that the Nuclein Hand-Held PCR Test will require FDA regulatory clearance and is intended for use in consultation with a medical professional, in person or via telemedicine.
Overview of the Nuclein Hand-Held PCR Test
Intended for use in consultation with health care professionals, in person or via telemedicine, the Nuclein Hand-Held PCR Test is a disposable, all-in-one test for infectious disease diagnosis. It uses standard, real-time PCR, requires no technical expertise and delivers battery-powered, sample-to-answer results within one hour, without the need to mail in a sample.
The Nuclein Hand-Held PCR Test device is designed to accept a swab or saliva sample directly from patients. The real-time PCR diagnostic process can be activated by simply pushing a button, after which point the device automatically prepares and analyzes the sample. The negative or positive test results are then automatically displayed on the LCD screen in under one hour.
The hand-held device is approximately the size and weight of a soda can (weight: 12 oz, dimensions: 6” long, 2” wide and 3” tall) and composed of a combination of plastic and aluminum.
Polymerase chain reaction (PCR) is a widely used technology and accepted as the gold standard in nucleic acid detection. It is the same technology used by the U.S. Centers for Disease Control and Prevention (CDC), other government agencies and commercial labs to confirm infections such as influenza and COVID-19.
Application for COVID-19
The disposable Nuclein Hand-Held PCR Test device provides PCR point-of-care results in less than one hour without the need for additional instruments. This supplements the current testing paradigm, the limitations of which are discussed on our Challenge page. These hand-held PCR devices can be rapidly and widely deployed to wherever they are needed and serve as a self-test when employed in conjunction with telemedicine.
See Full Press Release: Media Briefing: Nuclein Speeds Commercialization of First Ever Hand-Held PCR Test to Aid in COVID-19 Pandemic | Business Wire
Legacy MedSearch has more than 30 years of combined experience recruiting in the medical device industry. We pride ourselves on our professionalism and ability to communicate quickly and honestly with all parties in the hiring process. Our clients include both blue-chip companies and innovative startups within the MedTech space. Over the past 10 years, we have built one of the strongest networks of device professionals ranging from sales, marketing, research & , quality & regulatory, project management, field service, and clinical affairs.
We offer a variety of different solutions for hiring managers depending on the scope and scale of each individual search. We craft a personalized solution for each client and position with a focus on attracting the best possible talent in the shortest possible time frame.
Are you hiring?
Contact us to discuss partnering with Legacy MedSearch on your position.